

GOVERNMENT OF INDIA
MINISTRY OF HEALTH AND FAMILY WELFARE
DIRECTORATE GENERAL OF HEALTH SERVICES
REGIONAL DRUGS TESTING LABORATORY
SIX-MILE, GUWAHATI-781 022
Tel. No-0361-2338555, Fax No. 0361-2330555
Email: rdtlguwahati@cdsco.nic.in



No. RDTL/Report/S/2026-2027/A.N.29890/ 181-182

Date: 20/05/2026

To,

Mrs. Zarzokimi
Assistant Drugs Inspector (F&D)
CMO Office, Champhai-796321
Mizoram

Subject: Test report in Form 13 of sample under Drugs and Cosmetics Act, 1940 and Rules, 1945 thereunder-regarding.

Ref. No.: 381/26

Dated: 23/01/2026

Sir,

With reference to above, please find herewith the enclosed test report in Form 13 (in triplicate) of the sample received by the laboratory.

Kindly acknowledge the receipt of the same.

Yours sincerely,

(Rinku Kalita)
Government Analyst
RDTL, Guwahati

Copy for information to: The Drugs Controller, Mizoram.

(Rinku Kalita)
Government Analyst
RDTL, Guwahati

NSQ
DD-III

27/5/26

Adp
27/5/26
AD

MM
27/5



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

- Name of Inspector from whom received : Mrs. Zarzokimi Assistant Drugs Inspector (Food and Drugs) C.M.O Office
Champhai-796321 Mizoram
- Serial No. and date of Inspector's memorandum : 381/26 , 23-JAN-2026
- Number of Sample : Not mentioned.
- Date of receipt : 02-FEB-2026
- Names of drugs purporting to be contained in the sample : Albendazole Tablets I.P. 400 mg (Bengo-400 Tablets)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2026-27/0111	GUW/LS/2026-27/95	AT25/120	May-2025 Apr-2027	NA	Accuwell Medics Private Limited, Survey No. 414, Ashwamegh Ind. Estate, Changodar Ahmedabad-382213 (Guj) India

6. Condition of seals on : Seals were intact & identical to the specimen impression of the seal received from Drugs Inspector
[the packet or on portion of sample or container]

7. Result of test or analysis with protocols or test or analysis applied : Please see below

Date of Testing : From 07-May-2026 To 15-May-2026

COMPOSITION : Each Uncoated Chewable Tablet Contains:
Albendazole I.P. 400 mg

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	Peach colored, elongated, bi-convex, scored on one surface, uncoated tablets, in blister packing.	NA
2	Identification	Gives positive test for Albendazole.	NA
3	Average weight	0.70613 g	NA
4	Uniformity of weight	Complies.	±5% of avg. wt.

5	Dissolution (Stage- 1)	Does not comply. Release of Albendazole of each individual unit is found as follows: Unit 1=55.8%; Unit 2=58.07%; Unit 3=59.13%; Unit 4=55.64%; Unit 5=54.58%; Unit 6=59.89% . Release of Albendazole of all 06 units are found less than 85% of claim i.e. (Q+5%) where Q is 80% of claim.	Each unit is not less than Q+5% i.e. 85% of claim. where Q is 80%. (Specified in individual monograph)
6	Dissolution (Stage- 2)	Does not comply. Release of Albendazole of each individual unit is found as follows: Unit 1=58.98%; Unit 2=63.22%; Unit 3=60.95%; Unit 4=63.07%; Unit 5=64.89%; Unit 6=62.47%. Average release of Albendazole of 12 units (S1+S2) is 59.72% of claim which is less than Q i.e. 80% of claim. Release of all 12 units are found less than 65% of claim i.e. (Q-15%).	Average of 12 units (S1+S2) is equal or greater than 80% (Q) and no unit is less than 65 % of claim (Q-15%)
7	Dissolution (Stage- 3)	Does not comply. Release of Albendazole of all 12 units are found less than 65% i.e. (Q-15%).	Average of 24 units (S1+S2+S3) is equal to or greater than 80% (Q), Not more than 2 units are less than 65% (Q-15%) and no unit is less than 55% (Q-25%)

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
1	Albendazole	413.9 mg/Tablet	400 mg/Tablet	103.475	92.5 % to 107.5 %	I.P. 2022

In the opinion of the undersigned the sample referred to above **is not of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample does not comply as per I.P. 2022 with respect to the test for "Dissolution" of Albendazole.

Date: 20-MAY-2026

GOVERNMENT ANALYST
Rinku Kalita
 Government Analyst
 R.D.T.L., Guwahati-22

Report in the red colored paper indicates the sample is not of standard quality.

----- END OF REPORT -----